摘要
目的观察酒石酸美托洛尔片联合辛伐他汀片治疗冠心病心绞痛的效果。方法将96例冠心病心绞痛患者随机分为对照组和试验组,每组48例。对照组予以口服酒石酸美托洛尔12.5 mg bid,共3个月。试验组在对照组的基础上予以口服辛伐他汀10 mg qd,共3个月。比较2组临床疗效,血清血管内皮生长因子(VEGF)、基质金属蛋白酶抑制因子-1(TIMP-1)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)及心绞痛持续时间、发作次数,和药物不良反应发生情况。结果治疗后,试验组和对照组总有效率分别为95.83%(46例/48例)和81.25%(39例/48例),差异有统计学意义(P<0.05)。试验组和对照组血清VEGF分别为(79.47±9.21),(67.88±7.82)ng·L^(-1),TIMP-1分别为(331.04±41.02),(219.94±26.04)μg·L^(-1),MMP-2分别为(125.54±15.15),(185.67±33.16)μg·L^(-1),MMP-9分别为(178.62±24.82),(247.91±26.34)μg·L^(-1),心绞痛持续时间分别为(4.11±0.62),(5.45±0.72)min,发作次数分别为(3.19±0.38),(4.50±0.51)次/周,差异均有统计学意义(均P<0.05)。试验组和对照组的药物不良反应主要有头晕、上腹不适、窦性心动过缓,药物不良反应发生率分别为8.33%(4例/48例)和12.50%(6例/48例),差异无统计学意义(P>0.05)。结论酒石酸美托洛尔联合辛伐他汀治疗冠心病心绞痛的临床效果优于单用酒石酸美托洛尔,且安全性较高。
Objective To observe the efficacy and safety of metoprolol tartrate tablet in combination with simvastatin tablet in the treatment of coronary heart disease with angina pectoris. Methods A total of 96 patients with coronary heart disease and angina were randomly divided into control group and treatment group（ n = 48 cases）. The control group received oral administration of metoprolol tartrate 12. 5 mg twice daily. The treatment group received oral administration of simvastatin 10 mg once daily on the basis of the control group. Both groups were treated for 3 months. Clinical efficacy, serum vascular endothelial growth factor（ VEGF）,matrix metalloproteinases inhibitory factor 1（ TIMP-1）,matrix metalloprotei-nase-2（ MMP-2） and matrix metalloproteinases-9（ MMP-9）,angina duration,number of episodes and adverse drug reactions were compared between the two groups. Results Aftertreatment,total effective rate in the treatment group and control group was 95. 83%（ 46 cases/48 cases） and 81. 25%（ 39 cases/48 cases）,with significant difference（ P〈0. 05）. There were significant differences between the treatment group and the control group in the levels of serum VEGF [（ 79. 47 ± 9. 21） ng·L-（-1） vs（ 67. 88 ± 7. 82） ng·L-（-1）],TIMP-1 [（ 331. 04 ± 41. 02） μg·L-（-1） vs（ 219. 94 ± 26. 04） μg·L-（-1）],MMP-2 [（ 125. 54 ± 15. 15） μg·L-（-1） vs（ 185. 67 ± 33. 16） μg·L-（-1）],MMP-9 [（ 178. 62 ± 24. 82） μg·L-（-1） vs（ 247. 91 ± 26. 34） μg·L-（-1）],duration of angina pectoris [（ 4. 11 ± 0. 62） min vs（ 5. 45 ± 0. 72） min] and frequency of angina pectoris [（ 3. 19 ± 0. 38） times vs（ 4. 50 ± 0. 51） times per week]（ P〈0. 05）. The adverse drug reactions in the treatment group and control group were dizziness,epigastric discomfort,sinus bradycardia,and the incidences of adverse reactions in treatment group and control group were 8. 33%（ 4 cases/48 cases） and 12. 50%（ 6 cases/48 cases）,without sign
作者
付盈菊
刘志宁
宋玉新
FU Ying-ju;LIU Zhi-ning;SONG Yu-xin(Emergency Department, Tangshan Worker＇s Hospital, Tangshan 063000, Hebei Province, Chin)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2018年第8期922-925,共4页
The Chinese Journal of Clinical Pharmacology
基金
河北省卫生厅科研基金资助项目(10130246a)
关键词
冠心病心绞痛
酒石酸美托洛尔片
辛伐他汀片
coronary heart disease with angina pectoris
metoprolol tartrate tablet
simvastatin tablet
